Clinical Trial Phase III

Large-scale trials involving 1,000-3,000+ participants designed to confirm efficacy, monitor side effects, and compare the compound to existing standard treatments. Phase III trials provide the definitive evidence required for regulatory approval. These trials are randomized, often double-blinded, and may run for several years. Approximately 25-30% of compounds that enter Phase III ultimately receive FDA approval.